Overview

* Biote Q2 2025 revenue misses analyst expectations, per LSEG data

* Net income rises to $3.9 mln, driven by dietary supplement sales

* Company initiated reorganization to boost clinic and procedure growth

Outlook

* Biote ( BTMD ) revises 2025 revenue guidance to above $190 mln

* Company expects 2025 adjusted EBITDA above $50 mln

* Biote ( BTMD ) sees 2025 procedure revenue decreasing at high single-digit rate

* Company forecasts 2025 dietary supplement revenue to grow at mid-teens rate

Result Drivers

* DIETARY SUPPLEMENT SALES - Increased 30.4% year-over-year, contributing positively to revenue

* GROSS MARGIN EXPANSION - Improved to 71.6% due to vertical integration and cost management

* REORGANIZATION - Initiated restructuring to enhance productivity and drive long-term success

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $48.90 $49.50

Revenue mln mln (5

Analysts

)

Q2 EPS $0.1

Q2 $15.20

Adjusted mln

EBITDA

Q2 Gross 71.6%

Margin

Q2 31.1%

Adjusted

EBITDA

Margin

Q2 $10.80

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the professional information services peer group is "buy"

* Wall Street's median 12-month price target for Biote Corp ( BTMD ) is $7.00, about 40.4% above its August 5 closing price of $4.17

* The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)